For research use only. Not for therapeutic Use.
LLL12 is a small molecule inhibitor of STAT3 that inhibits STAT3 phosphorylation. LLL12 enhanced the inhibitory effect of Cisplatin (HY-17394) and Paclitaxel (HY-B0015) on ovarian cancer cell formation, migration, and growth[1].
LLL12 (0.01-1 μM; 72 h) inhibits cell viability of ovarian cancer cell lines with or without Cisplatin (0.5 μM, 2.5 μM) and Paclitaxel (0.25 μM, 0.5 μM).[1].
LLL12 (0.25-1.0 μM; 72 h) inhibit STAT3 phosphorylation (Tyr705) in ovarian cancer cell lines[1].
LLL12 (5 mg/kg; i.p.; once daily for 13 d) shows strong growth inhibition activity in mouse osteosarcoma cells and tumor growth[2].
| Catalog Number | I007679 |
| CAS Number | 1260247-42-4 |
| Synonyms | 5-hydroxy-9,10-dioxoanthracene-1-sulfonamide |
| Molecular Formula | C14H9NO5S |
| Purity | ≥95% |
| InChI | InChI=1S/C14H9NO5S/c15-21(19,20)10-6-2-4-8-12(10)14(18)7-3-1-5-9(16)11(7)13(8)17/h1-6,16H,(H2,15,19,20) |
| InChIKey | CQBHSRLUQDYPBU-UHFFFAOYSA-N |
| SMILES | C1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C(=CC=C3)S(=O)(=O)N |
| Reference | [1]. Zhang R, et al. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells. Oncol Rep. 2020 Sep;44(3):1224-1232. [2]. Onimoe GI, et al. Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice. Invest New Drugs. 2012 Jun;30(3):916-26. |
